Treatment of patients with poor response prognosis: Comparison of two protocols of pituitary suppression;Tratamiento de pacientes con pronóstico de baja respuesta: Comparación de dos protocolos de supresión hipofisaria

Revista Iberoamericana de Fertilidad y Reproduccion Humana

Volumn 22, Issue 2, 2005, Pages 123-130

  Marín Palazón, Marín ^a   Rubio Rubio, J M ^a   Sanchez Gutierrez M ^a   Urgal Ayala, A ^a   Monzo Miralles A ^a   Romeu Sarrio A ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

GnRH agonist; Gonadotropin releasing hormone (GnRH) antagonist; IVF; Poor response

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN DERIVATIVE; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ADULT; ARTICLE; CELL COUNT; CLINICAL PROTOCOL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE REGIMEN; EMBRYO; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HUMAN; HUMAN CELL; HYPOPHYSIS FUNCTION; INTRACYTOPLASMIC SPERM INJECTION; LUTEAL PHASE; MAJOR CLINICAL STUDY; METAPHASE; OOCYTE; OVARY FOLLICLE; OVULATION INDUCTION; PREGNANCY RATE; PROGNOSIS; QUALITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING;

EID: 23744514309     PISSN: 11320249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J.: Clinical management of low ovarian response to stimulation for IVF: a systematic review. Human Reproduction Update 2003; 9 (1): 61-76.
2. Torner J, Philput C, Jones G, Muasher S.: Basal follicle-stimulating hormone level is a better predictor of in vitro fertlization performance than age. Fertil Steril 1991; 55: 784-91.
3. Evers J, Slaats P, Land JA, Dumoulin JC, Dunselman GA.: Elevated levels of basal estradiol-17beta predict poor response in patients with normal basal levels of follicle-stimulating hormone undergoing in vitro fertilization. Fertil Steril 1998; 69 (6): 1010-4.
4. Seifer D, Lambert-Masserlian B, Hogan JW, Gardiner AC, Blazar AS and Berk CA.: Day 3 serun inhibin-B is predictive of assisted reproductive thecnologies outcome. Fertil Steril 1997; 67: 110-14.
5. Fawzy M LA, Harrison RF, Knight PG, Groome N, Hennelly B, Robertson WR.: Day 5 inhibin B levels in a treatment cycle are predictive of IVF outcome. Hum Reprod 2002; 17 (6): 1535-43.
6. Bancsi LF BF, Bijkemans MJ, de Jong FH, Habbema JD, te Velde ER.: Predictors of poor ovarian response in invitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril 2002; 77: 328-36.
7. Romeu M: El fallo ovárico oculto y su importancia en reproducción asistida: Valencia, 2000.
8. Loumaye E.: The control of endogenus secretion of LH by gonadotropin-releasing hormone agonist during ovarian hyperestimulation for in-vitro fertilization and embryo transfer. Hum Reprod 1990; 5: 357-76.
9. Cramer D, Powers DR, Oskowitz SP, Liberman RF, Hornsterin MD, Mcshane PM, et al.: Gonadotropin hormone agonists use in assisted reproduction cycles: the influence of long and short regimens on pregnancy rates. Fertil Steril 1999; 72: 83-89.
10. Kowalic A, Barmat L, Damario M, Lio HC, Davis O, Rosenwaksv Z.: Ovarian estradiol production in vivo. Inhibitory effect of leuprolide acetate. J. Reprod. Med 1998; 43: 413-17.
11. Leung PCK.: GnRH receptor and potential action in human ovary. Gynaecol Endocrinol 1999; 13: 10.
12. Al-Inany H, Alboulghar M.: Gonadotrophin-releasing hormone antagonists for assited conception (Corhrane review). The Cochrane Library 2004 (4).
13. Diedrich K, Diedrich C, Santos E et al.: Supression of the endogenus lutinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation. Hum Reprod 1994; 9: 788-91.
14. Albano C, Smitz J, Camus M et al.: Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopusal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix). Hum Reprod 1996; 11 (10): 2114-18.
15. Feldberg D, Parhi J, Ashkenazi J, Dicker D, Shalev J and Ben-Rafael Z.: Minidose gonadotropin reasing hormone agonist is the treatment of choice in poor responders with high FSH levels. Fertil Steril 1994; 62: 343-346.
16. Olivennes F, Righini C, Fanchin R, Torrisi C, Hazout A, Glissant M, Fernández H and Frydman F.: A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high FSH concentrations on day-3. Hum Reprod 1996; 11: 1169-72.
17. Rubio JM.: Análisis crítico de las estrategias para la prevención y tratamiento de la baja respuesta en fecundación in vitro.: Universidad de Valencia, 2002.
18. Craft I, Gorgy A, Hill J et al.: Will GnRH antagonists provide a new hope for patients considered 'dificult responders' to GnRH agonist protocols? Human Reproduction 1999; 14: 2959-62.
19. Akman M, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M.: Addition of GnRH antagonists in cycles of poor responders undergoing IVF. Hum Reprod 2000; 15: 2145-47.
20. Akman M, Erden HF, Tosun SB, Bayazit N, Aksoy E, M B.: Comparison of agonistic flare-up protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Human Reproduction 2001; 16 (5): 868-70.
21. Lin Y KJ, Hillensjo T.: Is there a diference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilisation either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist? Hum Reprod 1999; 14: 885-8.
22. Ortmann O, Oltmanns K, Weiss JM, et al.: Effects of the GnRH antagonist Cetrorelix on steroidogenesis in human granulosa lutein cells. Hum Reprod 1998; 13: 252.
23. Weiss J, Oltmanns K, Gürke EM, Polack S, Eick F, Felberbaum R, Diedrich K, Ortmann.: Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells. European Journal of Enndocrinology 2001; 144: 677-85.
24. Olivennes F, Belaisch-Allart J, Emperaire JC et al.: Prospective, randomized, controlled study of in-vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000; 73: 314-20.
25. Albano C, Felberbaum RE, Smitz J, et al.: Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 2000; 15: 526-31.